430 Shares in Illumina, Inc. $ILMN Acquired by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. acquired a new position in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 430 shares of the life sciences company’s stock, valued at approximately $41,000.

Other hedge funds also recently added to or reduced their stakes in the company. Rise Advisors LLC raised its holdings in Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 224 shares during the last quarter. Golden State Wealth Management LLC raised its holdings in Illumina by 123.2% in the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock worth $42,000 after acquiring an additional 292 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Illumina by 2,936.8% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock worth $46,000 after acquiring an additional 558 shares during the last quarter. WPG Advisers LLC purchased a new position in Illumina in the 1st quarter worth approximately $58,000. Finally, Blue Trust Inc. raised its holdings in Illumina by 63.1% in the 2nd quarter. Blue Trust Inc. now owns 654 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 253 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Trading Up 0.1%

NASDAQ:ILMN opened at $100.11 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm has a market capitalization of $15.39 billion, a price-to-earnings ratio of 12.67, a price-to-earnings-growth ratio of 2.47 and a beta of 1.40. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The business has a fifty day moving average price of $98.17 and a 200-day moving average price of $91.76.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.Illumina’s revenue was down 4.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Evercore ISI decreased their target price on shares of Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Illumina in a research note on Saturday. Morgan Stanley boosted their target price on shares of Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, August 4th. Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, Citigroup lowered shares of Illumina from a “hold” rating to a “strong sell” rating and decreased their target price for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th. Five investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $115.25.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.